Artivion, Inc. (AORT)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-02-12

Key Insights

  • Artivion reported its Q4 2025 financial results, showing revenue growth of 8% year-over-year and a 120 basis point improvement in gross margins.
  • The company provided guidance for fiscal year 2026, forecasting revenue growth of 10-12% and continued margin expansion.
  • Artivion announced the appointment of a new Chief Commercial Officer with extensive experience in the medical device industry, signaling its focus on commercial execution.
Filing tone (AI): Positive
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Artivion, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.